Sunday, 18 February 2018

Pfizer and Merck KGaA suffered another setback with immuno-oncology med Bavencio

Pfizer and Merck KGaA have suffered another setback with immuno-oncology med Bavencio—and this one’s raising some eyebrows.
Thursday, the companies revealed Bavencio (avelumab) had failed to outdo chemo at extending the lives of second-line lung cancer patients with PD-L1-positive tumors. And the way Evercore ISI analyst Umer Raffat sees it, there’s no “good reason” to explain the flop.

No comments:

Post a Comment

Fat, not carbs, is directly linked to weight gain

The research looked at mice on 30 different types of diets. The result of the research found that the mice on a high-fat, low-carb diet ga...